PF-Atlas › Clinical Trials › NCT05060822

Phase ll Study of HEC585 in Patients With IPF

HEC585 · Phase 2

Registry ID
NCT05060822
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
HEC585
Sponsor
Sunshine Lake Pharma Co., Ltd.
Start
2021-06-30
Enrollment
270
Locations
1

About this trial

A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in patients with idiopathic pulmonary fibrosis

View NCT05060822 on ClinicalTrials.gov →

Explore related

All HEC585 trialsAll IPF trials

Related trials

HEC585 — NCT03092102HEC585 — NCT05383131HEC585 — NCT04512170
Medical disclaimer. This page summarizes public trial data for NCT05060822 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.